ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "population studies"

  • Abstract Number: 2036 • ACR Convergence 2020

    Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling

    Ariane Barbacki1, Murray Baron2, Mianbo Wang3, Yuqing Zhang4, Mandana Nikpour5 and Ada Man6, 1McGill University Health Center, Montreal, QC, Canada, 2Jewish General Hospital, Montreal, QC, Canada, 3Lady Davis institute for Medical Research, Montreal, QC, Canada, 4Massachusetts General Hospital, Harvard Medical School, Boston, 5The University of Melbourne at St. Vincent's Hospital, Melbourne, Victoria, Australia, 6University of Manitoba, Winnipeg, MB, Canada

    Background/Purpose: Systemic sclerosis (SSc) is a rare systemic autoimmune disease associated with a high mortality and characterized by the accrual of organ damage over time.…
  • Abstract Number: 0541 • ACR Convergence 2020

    Suboptimal Vaccination Coverage with Influenza, Pneumococcal and Herpes Zoster Vaccines Among Adult Patients with Autoimmune Inflammatory Rheumatic Diseases in a Nationwide Health Care Plan

    Victoria Furer1, Clara Weil2, Melanie Orin2, Gabriel Chodick2, Varda Shalev2, Yonit Fisher Shoval3, Raanan Cohen3 and Ori Elkayam4, 1Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 2Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel, 3Abbvie, Hod Hasharon, Israel, 4Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel

    Background/Purpose: Autoimmune inflammatory rheumatic diseases (AIIRD) increase the susceptibility to infections. Immunisation against vaccine-preventable diseases is recommended for patients with AIIRD by most international medical…
  • Abstract Number: 0561 • ACR Convergence 2020

    Risk Factors for Falls Among Individuals with Knee OA: A Longitudinal Community-based Study

    Jessica Wilfong1, Anthony Perruccio2 and Elizabeth Badley2, 1Krembil Research Institute, University Helath Network, Toronto, ON, Canada, 2Krembil Research Institute, UHN; University of Toronto, Toronto, ON, Canada

    Background/Purpose: Knee osteoarthritis (OA) is a known risk factor for falling, but little is known about what factors contribute to the risk of falling among…
  • Abstract Number: 0014 • ACR Convergence 2020

    Does the Type of Rheumatic Disease or Biologic Treatment Increase the Risk of Developing Severe COVID-19?

    Fernando López-Gutierrez1, Antía García-Fernández1, Jesús Loarce-Martos1, Laura Calvo-Sanz1, Ivan Del Bosque-Granero2, Veronica Garcia2, Boris Blanco-Cáceres1, Cristina Pijoan-Moratalla1, Lourdes Villalobos-Sánchez3, Javier Bachiller-Corral1 and Mónica Vázquez1, 1Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, 2Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, 3Rheumatology, Hospital Universitario Ramón y Cajal, Madrid

    Background/Purpose: Patients with inflammatory rheumatic diseases (IRD) have an increased risk for infection related to immunosuppression secondary to their disease, treatment and comorbidities. Nonetheless recent…
  • Abstract Number: 0562 • ACR Convergence 2020

    The Relationship Between Heart Disease Risk Profile and Osteoarthritis, Overall and by Multi-/Single-Joint Involvement

    Anthony Perruccio1, Shatabdy Zahid2, Calvin Yip3, J Denise Power2, Mayilee Canizares2, George Heckman4 and Elizabeth Badley1, 1Krembil Research Institute, UHN; University of Toronto, Toronto, ON, Canada, 2Krembil Research Institute, University Health Network, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada, 4University of Waterloo, Waterloo, ON, Canada

    Background/Purpose: Osteoarthritis (OA) and heart disease (HD) are among the most common chronic conditions. Several studies have shown that OA increases the risk of HD…
  • Abstract Number: 0016 • ACR Convergence 2020

    Differential Characteristics in Inflammatory Rheumatologic Patients with Severe and Mild COVID-19 Infection

    Paula García Escudero1, Claudia Stoye2, Orlando Pompei fernández2, Marta González Fernández1, Joaquín María Belzunegui Otano3, Juan Ramón De Dios2, Belén Álvarez Rodríguez2, Elena Garmendia Sánchez1, Susana Gil2, Ana Ruibal-Escribano4, Margarida Vasques Rocha2, Francisco García Llorente5, César Antonio Egües6, Edurne Guerrero7 and Jaime Calvo-Alén2, 1Hospital Universitario Cruces, Barakaldo, Spain, 2Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, 3Rheumatology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Spain, 4Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, 5Hospital Universitario de Galdakao, Galdakao, Pais Vasco, Spain, 6Hospital Universitario Donostia, Donostia-San Sebastián, Pais Vasco, Spain, 7Hospital Alto Deba, Arrasate, Pais Vasco, Spain

    Background/Purpose: SARS COV 2 pandemic has been an issue which has challenged the health care systems around the world. Rheumatology has been involved in two…
  • Abstract Number: 0566 • ACR Convergence 2020

    Healthcare Utilization and Costs Prior to Diagnosis of ANCA Vasculitis in Medicare Beneficiaries

    Shirley Huang1, Xintong Li2, Joehl Nguyen2, Jacob Robinson2, Susan Hogan3, Vimal Derebail3 and Carolyn Thorpe2, 1University of North Carolina at Chapel Hill, Chapel Hill, 2University of North Carolina Eshelman School of Pharmacy, Chapel Hill, 3University of North Carolina Kidney Center, Chapel Hill

    Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA) vasculitis (AV) is a complex group of autoimmune disorders affecting blood vessels in multiple organ systems. Delays in diagnosis are…
  • Abstract Number: 058 • 2020 Pediatric Rheumatology Symposium

    Kawasaki Disease in Ontario Children from 1995-2017: A Population-based Descriptive Analysis

    Cal Robinson 1, Rahul Chanchlani 1, Megan Schlorff 1, Francis Lao 1, Tapas Mondal 1, Catherine Demers 1, Elizabeth Darling 1, Sandeep Brar 2, Rulan Parekh 3, Hsien Seow 1, Eric Benchimol 4 and Michelle Batthish1, 1McMaster University, Hamilton, Canada, 2University of California, San Fransisco, 3University of Toronto, Toronto, Canada, 4University of Ottawa, Ottawa, Canada

    Background/Purpose: Kawasaki disease (KD) is a childhood vasculitis with rising global incidence and the most common cause of childhood acquired heart disease in the developed…
  • Abstract Number: 893 • 2019 ACR/ARP Annual Meeting

    The Presence of Extractable Nuclear Antigens (ENA) Antibodies in a Large Population-based Cohort from the Netherlands and Their Association with Known Risk Factors for Systemic Lupus Erythematosus and Primary Sjögren Syndrome

    Petra Yntema-Eckenhaussen 1, Suzanne Arends 1, Elisabeth Brouwer 2, Caroline Roozendaal 3, Hendrika Bootsma 4, Johanna Westra 1 and Karina de Leeuw1, 1Dept. of Rheumatology and Clinical Immunology - University Medical Center Groningen (UMCG), University of Groningen, Groningen, Netherlands, 2Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 3Dept. of Laboratory Medicine - University Medical Center Groningen (UMCG), University of Groningen, Groningen, Netherlands, 4University of Groningen, Groningen, Netherlands

    Background/Purpose: Previous studies have demonstrated that years before clinical onset of auto-immune diseases, auto-antibodies can already be present. However, it is also known that some…
  • Abstract Number: 2084 • 2019 ACR/ARP Annual Meeting

    Why so Fast? A Focus on Reasons for an Increase in Arthritis-Attributable Activity Limitation Trends, 2002-2017

    Kristina Theis1, Michael Boring 2 and Ross Wilkie 3, 1Centers for Disease Control and Prevention, Atlanta, 2Johnson Consulting dba Cutting Edge Technologies and Solutions, Atlanta, 3Keele University, Keele, United Kingdom

    Background/Purpose: “Arthritis-attributable activity limitation” (AAAL) is linked to many potentially modifiable characteristics (e.g., work disability, physical inactivity, obesity). By 2015, prevalence of AAAL among adults…
  • Abstract Number: 2189 • 2019 ACR/ARP Annual Meeting

    Reference Curves for the Knee Injury and Osteoarthritis Outcome Score in the Middle-aged Dutch Population

    Marieke Loef1, Féline PB Kroon 1, Stephan Böhringer 1, Frits R Rosendaal 1 and Margreet Kloppenburg 1, 1Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands

    Background/Purpose: The Knee injury and Osteoarthritis Outcome Score (KOOS) questionnaire is a widely used patient-reported outcome tool, developed to evaluate short- and long-term knee symptoms…
  • Abstract Number: 2676 • 2019 ACR/ARP Annual Meeting

    Cardiovascular Treatment and the Incidence of Giant Cell Arteritis (GCA) – a Population-Based Case-Control Study

    Aladdin Mohammad1, Pavlos Stamatis 1 and Aleksandra Turkiewicz 2, 1Lund University, Lund, Skane Lan, Sweden, 2Lund University, Lund, Sweden

    Background/Purpose: The aetiology of giant cell arteritis (GCA) is largely unknown. We aimed to evaluate ACE-inhibitors (ACE-i), angiotensin II receptor blockers (ARBs), beta-blocking agents, calcium…
  • Abstract Number: 1588 • 2018 ACR/ARHP Annual Meeting

    Risk of Cancer in Patients with Psoriasis/Psoriatic Arthritis: A Population-Based Study in the Province of British Columbia

    Julia Tan1, J. Antonio Avina-Zubieta2, Alyssa Dominique3, Hamid Tavakoli4 and Teresa A Simon3, 1Medicine, University of British Columbia, Vancouver, BC, Canada, 2Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, 3Bristol-Myers Squibb, Princeton, NJ, 4Arthritis Research Canada, Vancouver, BC, Canada

    Background/Purpose: Psoriasis (PsO) is a relapsing chronic autoimmune disease of the skin. Up to one-third of patients (pts) also develop inflammatory arthritis, known as psoriatic…
  • Abstract Number: 2417 • 2018 ACR/ARHP Annual Meeting

    Pregnancy Outcomes in Systemic Lupus Erythematous and Pre-Systemic Lupus Erythematous: A Population-Based Cohort Study

    A. Nicole Wade1, Mary A. De Vera2, Eric C. Sayre3 and J. Antonio Avina-Zubieta4, 1Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada, 2Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, 3Arthritis Research Canada, Richmond, BC, Canada, 4Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: The adverse effects of systemic lupus erythematosus (SLE) on maternal and fetal outcomes in pregnancy have been explored mainly in clinic-based cohorts. However, data…
  • Abstract Number: 2954 • 2018 ACR/ARHP Annual Meeting

    Factors Related to Initiation of TNF Inhibitor Versus Triple Therapy in Rheumatoid Arthritis Patients

    Yinzhu Jin1, Eun Ha Kang2, Angela Tong1, Rishi J. Desai3 and Seoyoung C. Kim4,5, 1Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), 3Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 4Division of Pharmacoepidemiology and Pharmocoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 5Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: While efficacy of triple therapy [methotrexate (MTX), sulfasalazine (HCQ), and sulfasalazine (SSZ)] and TNF inhibitor (TNFi) plus MTX was similar in a previous clinical…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology